Survival of high grade glioma patients depends on their age at diagnosis.

Cancer Biol Ther

Molecular Mutagenesis and DNA Repair, Istituto Nazionale Ricerca Cancro, Genova, Italy.

Published: September 2009

Background: Although the prognosis for malignant gliomas is normally dismal, it's not infrequent in neurooncologist's experience to find cases with unusually prolonged survival. In order to understand what factors influence survival of high grade glioma patients, a cohort of 196 high (III-IV) grade glioma patients was investigated for possible association between (1) survival and age at diagnosis; (2) survival and micronuclei in tumor tissue; (3) survival and gender; (4) micronuclei in tumor tissue and age at diagnosis.

Results: Patients diagnosed at an older age (>64 years) had a significantly higher hazard as compared to younger patients (
Methods: Survival analysis was performed by the Cox' proportional hazards regression model.

Conclusions: Age at diagnosis, together with other established prognostic factors such as histologic characteristics, extent of surgery and Karnofsky Performance Score may to a certain extent predict survival of high grade glioma patients.

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.8.18.9209DOI Listing

Publication Analysis

Top Keywords

grade glioma
12
glioma patients
12
survival high
8
high grade
8
age diagnosis
8
micronuclei tumor
8
tumor tissue
8
survival
6
patients
5
patients depends
4

Similar Publications

VASARI 2.0: a new updated MRI VASARI lexicon to predict grading and status in brain glioma.

Front Oncol

December 2024

NeuroRadiology Unit, Ospedale del Mare, Azienda Sanitaria Locale Napoli 1 Centro (ASL NA1 Centro), Naples, Italy.

Introduction: Precision medicine refers to managing brain tumors according to each patient's unique characteristics when it was realized that patients with the same type of tumor differ greatly in terms of survival, responsiveness to treatment, and toxicity of medication. Precision diagnostics can now be advanced through the establishment of imaging biomarkers, which necessitates quantitative image acquisition and processing. The VASARI (Visually AcceSAble Rembrandt Images) manual annotation methodology is an ideal and suitable way to determine the accurate association between genotype and imaging phenotype.

View Article and Find Full Text PDF

Programs allowing access to investigational drugs and off-label drug use for serious diseases have often been applied to pediatric cancers. A clinical study conducted under the Japanese "Patient-Proposed Healthcare Services" evaluated the efficacy and safety of dabrafenib plus trametinib in children with BRAF V600 mutant glioma (jRCTs071210071). This study successfully provided unapproved and off-label medications to four enrolled patients, two with low-grade glioma and two with high-grade glioma (median age: 10.

View Article and Find Full Text PDF

Background: Irinotecan demonstrates anti-tumor efficacy in preclinical glioma models but clinical results are modest due to drug delivery limitations. Convection enhanced delivery (CED) improves drug delivery by increasing intratumoral drug concentration. Real-time magnetic resonance imaging of infusate delivery during CED may optimize tumor coverage.

View Article and Find Full Text PDF

Over the past two decades, despite the emergence of various novel therapies for glioblastoma, patient survival outcomes remain poor, particularly in the recurrent stage of the disease. Cesium-131 (Cs-131) brachytherapy presents a promising treatment option for patients with newly diagnosed and recurrent brain neoplasms, enabling the initiation of radiation therapy at the time of tumor resection. This approach eliminates the typical delay in therapy following surgery and the need for multiple return visits for fractionated external beam radiotherapy.

View Article and Find Full Text PDF
Article Synopsis
  • Recurrent high-grade gliomas pose a treatment challenge; this study evaluates the effectiveness and tolerability of Hypofractionated Stereotactic Radiation (HFSRT) in re-irradiation.
  • A retrospective analysis of 52 patients treated between 2011 and 2021 showed median overall survival of 12 months, with re-irradiation doses differing among patients.
  • The treatment was mostly well-tolerated, with minimal severe side effects, indicating HFSRT as a promising option for managing these tumors.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!